AC Immune SA (ACIU)

NGM – Цена в реальном времени. Валюта: USD

2.77

-0.06 (-2.12%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.82

+0.05 (1.81%)

После закрытия: May 12, 2026, 5:33 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

AC Immune SA (ACIU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AC Immune SA (ACIU)

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

Видео

No Data

Пресс-релизы

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

Search stocks

AC Immune SA (ACIU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AC Immune SA (ACIU)

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Why AC Immune Stock Zoomed Almost 15% Higher Today

Видео

No Data

Пресс-релизы

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly